Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100541 | 1.00 | HDAC1 (0.47) | HDAC1HDAC2HDAC3NCOR2BMP1 | |
| SCHEMBL10170384 | 0.83 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2BMP1 | |
| SCHEMBL409375 | 0.83 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2BMP1 | |
| SCHEMBL409376 | 0.83 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2BMP1 | |
| SCHEMBL29573114 | 0.81 | GRM2 (0.42) | HDAC1HDAC2HDAC3NCOR2BMP1 | |
| SCHEMBL6791575 | 0.81 | GRM2 (0.42) | HDAC1HDAC2HDAC3NCOR2BMP1 | |
| SCHEMBL4147838 | 0.81 | HDAC1 (0.56) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL10206928 | 0.80 | HDAC1 (0.40) | HDAC1HDAC2HDAC3NCOR2CTSL | |
| SCHEMBL2205836 | 0.80 | HDAC3 (0.47) | HDAC1HDAC2HDAC3NCOR2CTSL | |
| SCHEMBL408595 | 0.78 | HDAC1 (0.41) | HDAC1HDAC2HDAC3NCOR2BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646022-B1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646022-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8486918-B2 | Phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012074732-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8192948-B1 | Chemifluorescent substrate for peroxide and peroxidase detection | PIERCE BIOTECHNOLOGY, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-0361470-B1 | Method for the chemiluminescence assay of the activity of peroxidase | FUJIREBIO KK (JP) | 1993-12-22 | — | — | EP | disclosed |
| US-5171668-A | Measuring light emitted from contacting (iso)luminol, peroxide, peroxidase activity enhancer, such as indoanilines, phenolindophenol and N-methylphenothiazine, with labeled peroxidase antibody-antigen complex | FUJIREBIO INC. (JP) | 1992-12-15 | — | — | US | disclosed |
| EP-0361470-A2 | Method for the chemiluminescence assay of the activity of peroxidase | FUJIREBIO INC. (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142745-A1 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | HDAC1 1320/4885HDAC2 1084/4885HDAC3 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.